Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals Plc ADR (NQ: CNTA )

3.750 +0.180 (+5.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 71,357
Open 3.640
Bid (Size) 1.640 (2)
Ask (Size) 4.590 (2)
Prev. Close 3.570
Today's Range 3.400 - 3.790
52wk Range 2.885 - 9.950
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
 
Via Benzinga
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
From Centessa Pharmaceuticals plc
Via Globe NewsWire

Performance

YTD
+19.81%
+19.81%
1 Month
+11.28%
+11.28%
3 Month
+14.33%
+14.33%
6 Month
-16.29%
-16.29%
1 Year
-57.58%
-57.58%

More News

Read More
NASDAQ: CNTA Investor Alert: Deadline on November 28, 2022 in Lawsuit against Centessa Pharmaceuticals plc
Via SBWire
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
Via SBWire
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
From Centessa Pharmaceuticals plc
Via Globe NewsWire
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
From Centessa Pharmaceuticals plc
Via Globe NewsWire
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
From Centessa Pharmaceuticals plc
Via Globe NewsWire
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
From Centessa Pharmaceuticals plc
Via Globe NewsWire
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
From Centessa Pharmaceuticals plc
Via Globe NewsWire
Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Centessa Pharmaceuticals plc (CNTA) Investors of Class Action Deadline and Encourages Investors to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
CENTESSA PHARMACEUTICALS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA
From Kahn Swick & Foti, LLC
Via Business Wire
CENTESSA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
From Centessa Pharmaceuticals plc
Via Globe NewsWire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
From Centessa Pharmaceuticals plc
Via Globe NewsWire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via Globe NewsWire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Barclays, Warner Bros., Olo, and Centessa and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa, PayPal, Opendoor, and Schmitt and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.